EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open access · CC BY-NC 4.0

A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease

Fred Reid, Dave Singh, Muna Albayaty, Rachel Moate, Eulalia Jimenez, Muhammad Waqas Sadiq, David Howe, Monica Gavala, Helen Killick, Adam Williams, Surekha Krishnan, Alex Godwood and 9 more

Clinical Pharmacology & Therapeutics · 2024-03 · 115 (3) · 565-575

DOI: 10.1002/cpt.3147 ↗

At a glance

Randomisierte kontrollierte Studie in Clinical Pharmacology & Therapeutics, published online on 2024-01-24. Written by Fred Reid and 20 co-authors. Institution: Clinical Development, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Major MEDLINE topics: Interleukin-33, Pulmonary Disease, Chronic Obstructive. Cited 52 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Tozorakimab is a human monoclonal antibody that neutralizes interleukin (IL)‐33. IL‐33 is a broad‐acting epithelial “alarmin” cytokine upregulated in lung tissue of patients with chronic obstructive pulmonary disease (COPD). This first‐in‐human, phase I, randomized, double‐blind, placebo‐controlled study (NCT03096795) evaluated the safety, tolerability, pharmacokinetics (PKs), immunogenicity, target engagement, and pharmacodynamics (PDs) of tozorakimab. This was a 3‐part study. In part 1, 56 healthy participants with a history of mild atopy received single escalating doses of either intravenous or subcutaneous tozorakimab or placebo. In part 2, 24 patients with mild COPD received multiple ascending doses of subcutaneous tozorakimab or placebo. In part 3, 8 healthy Japanese participants received a single intravenous dose of tozorakimab or placebo. The safety data collected included treatment‐emergent adverse events (TEAEs), vital signs, and clinical laboratory parameters. Biological samples for PKs, immunogenicity, target engagement, and PD biomarker analyses were collected. No meaningful differences in the frequencies of TEAEs were observed between the tozorakimab and placebo arms. Three tozorakimab‐treated participants with COPD experienced treatment‐emergent serious adverse events. Subcutaneous or intravenous tozorakimab demonstrated linear, time‐independent PKs with a mean half‐life of 11.7–17.3 days. Treatment‐emergent anti‐drug antibody frequency was low. Engagement of tozorakimab with endogenous IL‐33 in serum and nasal airways was demonstrated. Tozorakimab significantly reduced serum IL‐5 and IL‐13 levels in patients with COPD compared with placebo. Overall, tozorakimab was well tolerated, with a linear, time‐independent serum PK profile. Additionally, biomarker studies demonstrated proof of mechanism. Overall, these data support the further clinical development of tozorakimab in COPD and other inflammatory diseases.

Subjects

MeSH terms (MEDLINE)

Interleukin-33Pulmonary Disease, Chronic ObstructiveAdultHumansAntibodies, MonoclonalCytokinesDouble-Blind MethodBiomarkersHealthy Volunteers

Substances

Interleukin-33Antibodies, MonoclonalCytokinesBiomarkers

Authors and institutions

  • Clinical Development, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Medicines Evaluation Unit, Manchester University NHS Foundation Trust, University of Manchester, Manchester, UK.
  • Parexel International, Early Phase Clinical Unit, Northwick Park Hospital, Harrow, UK.
  • Early Biostatistics and Statistical Innovation, Data Science and AI, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Barcelona, Spain.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

Cite

APA

Reid, F., Singh, D., Albayaty, M., Moate, R., Jimenez, E., Sadiq, M. W., Howe, D., Gavala, M., Killick, H., Williams, A., Krishnan, S., Godwood, A., Shukla, A., Hewitt, L., Lei, A., Kell, C., Pandya, H., Newcombe, P., White, N., …, & Cohen, E. S. (2024). A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease. Clinical Pharmacology & Therapeutics, 115(3), 565-575. https://doi.org/10.1002/cpt.3147

Vancouver

Reid F, Singh D, Albayaty M, Moate R, Jimenez E, Sadiq MW, et al. A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease. Clinical Pharmacology & Therapeutics. 2024;115(3):565-575. doi:10.1002/cpt.3147

BibTeX
@article{Reid2024,
  author = {Reid, Fred and Singh, Dave and Albayaty, Muna and Moate, Rachel and Jimenez, Eulalia and Sadiq, Muhammad Waqas and Howe, David and Gavala, Monica and Killick, Helen and Williams, Adam and Krishnan, Surekha and Godwood, Alex and Shukla, Animesh and Hewitt, Lisa and Lei, Alejhandra and Kell, Chris and Pandya, Hitesh and Newcombe, Paul and White, Nicholas and Scott, Ian C and Cohen, E Suzanne},
  title = {A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  volume = {115},
  number = {3},
  pages = {565--575},
  doi = {10.1002/cpt.3147}
}
Start for free →